Literature DB >> 30067494

The Duration of the Amplified Sinus-P-Wave Identifies Presence of Left Atrial Low Voltage Substrate and Predicts Outcome After Pulmonary Vein Isolation in Patients With Persistent Atrial Fibrillation.

Amir Jadidi1, Björn Müller-Edenborn2, Juan Chen3, Cornelius Keyl4, Reinhold Weber5, Jürgen Allgeier5, Zoraida Moreno-Weidmann6, Dietmar Trenk7, Franz-Josef Neumann2, Heiko Lehrmann5, Thomas Arentz5.   

Abstract

OBJECTIVES: Left atrial (LA) low-voltage substrate (LVS) potentially slows intra-atrial conduction, which might identify patients at risk for arrhythmia recurrence following pulmonary vein isolation (PVI).
BACKGROUND: Up to 50% of patients with persistent atrial fibrillation (AF) have arrhythmia recurrence following PVI, mostly due to arrhythmogenic LA LVS.
METHODS: Seventy-two patients with persistent AF underwent electrocardioversion to sinus rhythm and high-density voltage mapping of the left atrium. Invasively measured LA activation time and P-wave duration (PWD; total PWD and LA PWD [measured from -dV/dt in leads V1 and V2 until the end of the P-wave]) on amplified (40 to 50 mm/mV, 100 to 200 mm/s) digitized 12-lead electrocardiography (ECG) were compared with the extent of LA LVS (<0.5 and <1. 0mV). Freedom from arrhythmia following PVI was evaluated in 143 patients with persistent AF stratified according to amplified PWD before ablation.
RESULTS: LA LVS resulted in regional conduction delay, which increased LA activation time (r = 0.79). LA PWD strongly correlated with LA activation time (r = 0.96) and LA LVS (r = 0.80). As the first (right atrial) portion of the P-wave (from P-wave beginning until -dV/dt in leads V1 and V2) was not affected by LA LVS, total PWD correlated with LA LVS (r = 0.84). PWD ≥150 ms identified advanced LA LVS with 94.3% sensitivity and 91.7% specificity. One-year arrhythmia freedom following PVI-only was significantly higher in patients with PWD <150 ms (n = 73) compared with those with prolonged PWD ≥150 ms (n = 70) (72.0% vs. 40.8%; p = 0.003).
CONCLUSIONS: Advanced arrhythmogenic LVS is associated with significant intra-atrial conduction delay, which is accurately measurable by prolongation of PWD on amplified 12-lead ECG. PWD ≥150 ms during sinus rhythm measured prior to ablation identifies patients with persistent AF who are at increased risk for arrhythmia recurrence following PVI.
Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ECG; atrial fibrillation; fibrosis; low voltage; risk marker; substrate

Mesh:

Year:  2018        PMID: 30067494     DOI: 10.1016/j.jacep.2017.12.001

Source DB:  PubMed          Journal:  JACC Clin Electrophysiol        ISSN: 2405-500X


  11 in total

Review 1.  Molecular Basis of Atrial Fibrillation Pathophysiology and Therapy: A Translational Perspective.

Authors:  Stanley Nattel; Jordi Heijman; Liping Zhou; Dobromir Dobrev
Journal:  Circ Res       Date:  2020-06-18       Impact factor: 17.367

2.  Prolonged P-wave duration in sinus rhythm pre-ablation is associated with atrial fibrillation recurrence after pulmonary vein isolation-A systematic review and meta-analysis.

Authors:  Raymond Pranata; Emir Yonas; Rachel Vania
Journal:  Ann Noninvasive Electrocardiol       Date:  2019-04-14       Impact factor: 1.468

Review 3.  Left Atrial Cardiomyopathy - A Challenging Diagnosis.

Authors:  Fabienne Kreimer; Michael Gotzmann
Journal:  Front Cardiovasc Med       Date:  2022-06-30

4.  Left Atrial Hypertension, Electrical Conduction Slowing, and Mechanical Dysfunction - The Pathophysiological Triad in Atrial Fibrillation-Associated Atrial Cardiomyopathy.

Authors:  Martin Eichenlaub; Bjoern Mueller-Edenborn; Jan Minners; Nikolaus Jander; Martin Allgeier; Heiko Lehrmann; Simon Schoechlin; Juergen Allgeier; Dietmar Trenk; Franz-Josef Neumann; Thomas Arentz; Amir Jadidi
Journal:  Front Physiol       Date:  2021-08-05       Impact factor: 4.566

5.  Electrocardiographic diagnosis of atrial cardiomyopathy to predict atrial contractile dysfunction, thrombogenesis and adverse cardiovascular outcomes.

Authors:  Björn Müller-Edenborn; Jan Minners; Cornelius Keyl; Martin Eichenlaub; Nikolaus Jander; Sherif Abdelrazek; Christoph Ahlgrim; Jürgen Allgeier; Heiko Lehrmann; Franz-Josef Neumann; Thomas Arentz; Amir Jadidi
Journal:  Sci Rep       Date:  2022-01-12       Impact factor: 4.379

6.  The Dose-Dependent Effects of Spironolactone on TGF-β1 Expression and the Vulnerability to Atrial Fibrillation in Spontaneously Hypertensive Rats.

Authors:  Mirong Tang; Yan Chen; Fuqing Sun; Liangliang Yan
Journal:  Cardiol Res Pract       Date:  2021-09-27       Impact factor: 1.866

7.  Usefulness of P-wave duration in patients with sick sinus syndrome as a predictor of atrial fibrillation.

Authors:  Yosuke Murase; Hajime Imai; Yasuhiro Ogawa; Naoaki Kano; Keita Mamiya; Tomoyo Ikeda; Kei Okabe; Kenji Arai; Shinji Yamazoe; Jun Torii; Katsuhiro Kawaguchi
Journal:  J Arrhythm       Date:  2021-07-21

8.  Echocardiographic and Electrocardiographic Determinants of Atrial Cardiomyopathy Identify Patients with Atrial Fibrillation at Risk for Left Atrial Thrombogenesis.

Authors:  Taiyuan Huang; Schurr Patrick; Louisa Katharina Mayer; Björn Müller-Edenborn; Martin Eichenlaub; Martin Allgeier; Jürgen Allgeier; Heiko Lehrmann; Christoph Ahlgrim; Marius Bohnen; Simon Schoechlin; Dietmar Trenk; Nikolaus Jander; Franz Josef Neumann; Thomas Arentz; Amir Jadidi
Journal:  J Clin Med       Date:  2022-02-28       Impact factor: 4.241

9.  Electrocardiogram characteristics of P wave associated with successful pulmonary vein isolation in patients with paroxysmal atrial fibrillation: Significance of changes in P-wave duration and notched P wave.

Authors:  Satoshi Yanagisawa; Yasuya Inden; Hiroya Okamoto; Aya Fujii; Yusuke Sakamoto; Keita Mamiya; Toshiro Tomomatsu; Rei Shibata; Toyoaki Murohara
Journal:  Ann Noninvasive Electrocardiol       Date:  2019-09-30       Impact factor: 1.468

10.  Echocardiographic diagnosis of atrial cardiomyopathy allows outcome prediction following pulmonary vein isolation.

Authors:  Martin Eichenlaub; Bjoern Mueller-Edenborn; Jan Minners; Martin Allgeier; Heiko Lehrmann; Juergen Allgeier; Dietmar Trenk; Franz-Josef Neumann; Nikolaus Jander; Thomas Arentz; Amir Jadidi
Journal:  Clin Res Cardiol       Date:  2021-04-29       Impact factor: 5.460

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.